Cryo-Cell International, Inc. CCEL AMEX · Healthcare · United States
$4.90 -9.35% -$0.51
Summary
40 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $1.43M against $577.2K.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 15 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Revenue grew by only 1.3% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.3% a year over 5 years. Over the last 3 years it grew by 1.3% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $2.82M.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $8.5 is 74% above today's price. 0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Processing And Storage Fees 99%
- Public Banking 0.4%
- Product 0.2%
By region
- FLORIDA 100%
Processing And Storage Fees brings in 99% of revenue.
Segments in detail